크로스포인트테라퓨틱스

CrossPoint Therapeutics is a biotechnology company founded in October 2022. We aim to become a leader in the development of new drugs using our proprietary Stealth-Body technology while prioritizing the well-being of the patient.

​

We strive to develop novel treatment options to refractory diseases with high unmet clinical demand using our antibody technology to provide a life free of suffering to patients.

CrossPoint Therapeutics strives to develop drugs that expands the range of curable disease as well as providing dignity and better life to patients. We will diversify our Fc inert antibody platform into various drug modalities to target indications that are challenging and in desperate need for therapeutics.

​To accomplish this mission, we are always open to actively collaborate.